Eli Lilly (LLY) Raises Bet to $21B as Obesity Pill War with Novo Nordisk Intensifies

U.S. pharma giant Eli Lilly (LLY) has pumped another $4.5 billion investment into its manufacturing facilities in Indiana, a key anchor of its domestic manufacturing buildout.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The figure has raised its investment in these facilities since 2020 to more than $21 billion. The company said the capital is to support the development of advanced commercial gene therapies and to produce Foundayo, its once-daily obesity pill. Obesity Pill Emerges as New Frontier in Weight-Loss Race The announcement comes days after the Indiana-based company smashed estimates for both its first-quarter 2026 profit and sales, with demand for its popular GLP-1 drugs, Zepbound for obesity and Mounjaro for type II diabetes, remaining robust. GLP-1, or glucagon-like peptide-1, is a hormone that manages blood sugar and appetite and plays a key role in weight-loss medications. Eli Lilly also stressed early signs of robust reception of Foundayo, which secured approval from U.S. regulatory authorities early last month and was prescribed nearly 1,400 times in its first week. However, key rival Denmark-based Novo Nordisk (NVO) — which beat Eli Lilly to the first oral weight-loss medication — is also seeing strong reception of its Wegovy pill. This helped the Danish pharma heavyweight to report stronger-than-expected first-quarter earnings and gave it the confidence to trim its adjusted sales and operating profit decline projection for the full fiscal year. Eli Lilly Boosts Domestic Manufacturing Buildout Meanwhile, apart from Foundayo, Eli Lilly also said the capital injection will go to the production of retatrutide, a drug in late-stage development that is targeted at treating both obesity and cardiometabolic diseases. The latter refers to conditions related to the heart and metabolism — or energy, sugar, and fat breakdown — problems. The investment is planned for two of Eli Lilly's three sites in Lebanon, Indiana. The first two are the Lilly Lebanon API for future production of active pharmaceutical ingredients and the Lilly Lebanon Advanced Therapies for genetic medicine development. The last one is the Lilly Medicine Foundry for the production of medicines for clinical trials. Eli Lilly said it has committed overall more than $50 billion in investments since 2020 to boost its U.S. manufacturing. Is Eli Lilly Still a Good Stock to Buy? On Wall Street, Eli Lilly's shares continue to enjoy a Strong Buy consensus rating from analysts. This is based on 19 Buys, two Holds, and one Sell issued by 22 analysts over the past three months. The rating comes with an average LLY price target of $1,262.85 that implies roughly 28% upside in the months ahead.